GlassScriptPhysician profile
John Garofalo
NPI 1730187774
$1,855.27
in general payments reported to CMS, 2019-2025
16 companies · $387 in 2025
The $387 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $191 · 2021: $179 · 2022: $144 · 2023: $198 · 2024: $213 · 2025: $387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $681.32 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $339.51 | 2022-2024 | Sotyktu |
| Amgen INC. | $152.30 | 2025 | Otezla, Otezla |
| Genzyme Corporation | $130.46 | 2020-2025 | |
| Pfizer INC. | $95.37 | 2019-2023 | |
| Abbvie INC. | $85.83 | 2019-2020 | |
| Celgene Corporation | $66.55 | 2019 | |
| Biofrontera INC. | $60.94 | 2019-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $60.21 | 2019-2024 | Dupixent |
| Mission Pharmacal Company | $39.12 | 2019 | |
| Leo Pharma INC. | $38.36 | 2025 | Anzupgo |
| Galderma Laboratories, L.P. | $29.44 | 2019-2024 | |
| Incyte Corporation | $22.67 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $19.00 | 2023 | |
| Lilly USA, LLC | $17.86 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $16.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Garofalo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.